Author:
Lu Yi-Ting,Rejiepu Buweimairemu,Zhang Di,Cai Dong-Cheng,Yang Kun-Qi,Tian Tao,Zhou Xian-Liang,Fan Peng
Abstract
<b><i>Introduction:</i></b> Neurofibromatosis type 1 (NF-1) is caused by mutations in the <i>NF1</i> gene that encodes neurofibromin, a negative regulator of RAS proto-oncogene. Approximately one-third of the reported pathogenic mutations in <i>NF1</i> are splicing mutations, but most consequences are unclear. The objective of this study was to identify the pathogenicity of splicing mutation in a Chinese family with NF-1 and determine the effects of the pre-mRNA splicing mutation by in vitro functional analysis. <b><i>Methods:</i></b> Next-generation sequencing was used to screen candidate mutations. We performed a minigene splicing assay to determine the effect of the splicing mutation on <i>NF1</i> expression, and three-dimensional structure models of neurofibromin were generated using SWISS-MODEL and PROCHECK methods, respectively. <b><i>Results:</i></b> A pathogenic splicing mutation c.479+1G>C in <i>NF1</i> was found in the proband characterized by childhood-onset refractory hypertension. In vitro analysis demonstrated that c.479+1G>C mutation caused the skipping of exon 4, leading to a glutamine-to-valine substitution at position 97 in neurofibromin and an open reading frame shift terminating at codon 108. Protein modeling showed that several major domains were missing in the truncated neurofibromin protein. <b><i>Conclusion:</i></b> The splicing mutation c.479+1G>C identified in a Chinese patient with NF-1 and childhood-onset refractory hypertension caused the skipping of exon 4 and a truncated protein. Our findings offer new evidence for the molecular diagnosis of NF-1.
Subject
Cardiology and Cardiovascular Medicine,Nephrology,Cardiology and Cardiovascular Medicine,Nephrology